TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01147393

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 90Y-epratuzumab tetraxetan
Description: The 90Y-epratuzumab treatment will begin one week after the 4th veltuzumab injection. Patients will receive unlabeled, unconjugated epratuzumab (1.5 mg/kg) that will be infused over \~30 minutes. All patients will then receive a 90Y-epratuzumab dose. Dose will be escalated by patient cohort either at 15 mCi/m2 or 20 mCi/m2. The second 90Y-epratuzumab treatment will be given at the same dose, 1 week after the first 90Y-epratuzumab dose.
Study: NCT01815580

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atripla or Stribild
Description: Antiretroviral therapy
Study: NCT02305875

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: MCN scoring
Description: Mcn's distance from top of the humeral head. Mcn's distance to the catheters insertion point. Mcn's distance and position in relationship to the axillary artery.
Study: NCT02375269

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: RIPC with a tourniquet
Study: NCT02680587

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: SBRT
Description: SBRT (1-5 fractions) will be administered.
Study: NCT00467714

Intervention type: PROCEDURE
Group type: NO_INTERVENTION
Intervention: rhinoplasty
Description: COLUMELLA STRUT PLACEMENT
Study: NCT01147393

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: veltuzumab
Description: Veltuzumab is given in 4 weekly doses, each 200 mg/m2.
Study: NCT02264288

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 30 x 10^6 cells
Description: 30 x 10\^6 Human Placenta Derived cells (PDA-002) administered intramuscularly on Study Days 1 and 8

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Identical matching placebo administered IM on Study Days 1 and 8
Study: NCT04001101

Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: RT and Anti-PD-1
Description: limited metastatic site radiation

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Anti-PD-1
Description: anti-PD-1 therapy alone
Study: NCT01481168

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Pacemaker implantation (Medtronic)
Description: DDD+/-R pacing
Study: NCT01787539

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Postoperative Chemotherapy
Description: Postoperative chemotherapy with EOX regimen: Epirubicin with intravenous bolus at a dose of 50 mg/m2 an on day 1; Oxaliplatin with intravenous infusion during a 2-hour period at a dose of 130 mg/m2; Capecitabine administrated orally at a twice daily dose of 625 mg /m2 during 21 days. Treatment cycles will be repeated every 3 weeks.~Postoperative chemotherapy will be administrated in patients with tumor regression grade 0, 1, 2 randomized to perioperative chemotherapy and will be initiated 6 to 12 weeks after surgery.
Study: NCT01481168

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Pacemaker implantation (Medtronic)
Description: ODO pacing
Study: NCT01935544

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Botulinum toxin injection
Study: NCT01481168

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Implantable Loop Recorder (Medtronic)
Description: Loop recorder implantation
Study: NCT01110772

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 2-octyl cyanoacrylate [InteguSEAL®]
Description: At operating room arrival prior to surgery, povidone-iodine is applied on the skin surface on concentric circles as recommended; after drying, the cyanoacrylate device is opened and a layer of the sealant is applied on the incision and skin site(IS100 for patients undergoing mastectomy, and IS200 for patients undergoing gynecologic or digestive tract surgeries).

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Iodine povacrylex in isopropyl alcohol [Duraprep®, 3M]
Description: At the operating room arrival a few minutes before the incision, cleansing and skin antisepsis is done with the prefilled device with iodine povacrylex in isopropyl alcohol as recommended by 3M.
Study: NCT04523584

Intervention type: DEVICE
Intervention: Magnetic Resonance Imaging (MRI)
Description: Participants will undergo MR imaging of the liver. Liver PDFF will be measured.

Intervention type: DEVICE
Intervention: Magnetic Resonance Imaging (MRI)
Description: Participants will undergo MR imaging of the liver. Liver PDFF will be measured.

Intervention type: DEVICE
Intervention: Ultrasound Imaging
Description: Participants will undergo ultrasound imaging of the liver. UDFF and shear wave speed (US-SWS) will be measured.

Intervention type: DEVICE
Intervention: Ultrasound Imaging
Description: Participants will undergo ultrasound imaging of the liver. UDFF and shear wave speed (US-SWS) will be measured.
Study: NCT00212121

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: high dose boost
Description: high dose boost

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: high dose boost
Description: high dose boost

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: boost
Description: low dose versus high dose

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: boost
Description: low dose versus high dose
Study: NCT01918540

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Hollow Centralizer
Description: The stem used (MS30)was originally designed with a solid centralizer but has been redesigned to be used with a hollow centralizer. The patients are randomized to either solid or hollow centralizer

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Solid Centralizer
Description: The stem used (MS30)was originally designed with a solid centralizer but has been redesigned to be used with a hollow centralizer. The patients are randomized to either solid or hollow centralizer

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: MS-30 femoral stem
Description: This is the stem used in the study.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: MS-30 femoral stem
Description: This is the stem used in the study.
Study: NCT04785859

Intervention type: DIAGNOSTIC_TEST
Intervention: BPD prediction
Description: The following lung ultrasounds will be performed on the patients included in the study: first 24 hours of life, 3rd day of life (DOL) and 7th DOL. At one week of life detection of proteins in nasopharyngeal aspirates will be performed. During the first week of life, an echocardiography will be performed in all patients to evaluate the possibility of a patent ductus arteriosus and its hemodynamic significance.~In the first 20 patients who remain intubated at one week of life, tracheal aspirates will be obtained too, to compare protein determination in both aspirates at the same time.

Intervention type: DIAGNOSTIC_TEST
Intervention: BPD prediction
Description: The following lung ultrasounds will be performed on the patients included in the study: first 24 hours of life, 3rd day of life (DOL) and 7th DOL. At one week of life detection of proteins in nasopharyngeal aspirates will be performed. During the first week of life, an echocardiography will be performed in all patients to evaluate the possibility of a patent ductus arteriosus and its hemodynamic significance.~In the first 20 patients who remain intubated at one week of life, tracheal aspirates will be obtained too, to compare protein determination in both aspirates at the same time.
Study: NCT00062010

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: interferon alpha
Description: Interferon alpha given subcutaneously, 6 million units per square meter of body surface area on days 1 and 2 of each week for 6 weeks, followed by 2 weeks of rest. Given until disease progression or unacceptable toxicity.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 13-cis-retinoic acid
Description: 13-cis-retinoic acid given at 1 mg/kg of body weight by mouth on days 1 and 2 of each week for 6 weeks, followed by 2 weeks of rest. Given until disease progression or unacceptable toxicity.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paclitaxel
Description: paclitaxel administered intravenously with premedication at 75 mg/m2 of body surface area on day 2 of each week for 6 weeks, followed by 2 weeks of rest. Given until disease progression or unacceptable toxicity.
Study: NCT04580121

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RO7283420
Description: RO7283420 will be administered to participants by intravenous (IV) infusion Q3W at a starting dose of 0.15mg. Starting dose levels (double step-up regimen, Q3W) for SC injections was the same as the highest dose levels that have been cleared in the IV double step-up cohorts at that timepoint. Each participant will receive up to 6, 9, and 18 cycles of treatment with RO7283420, when treated with Q3W, Q2W, or QW dosing regimens, respectively.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RO7283420
Description: RO7283420 will be administered to participants by intravenous (IV) infusion Q3W at a starting dose of 0.15mg. Starting dose levels (double step-up regimen, Q3W) for SC injections was the same as the highest dose levels that have been cleared in the IV double step-up cohorts at that timepoint. Each participant will receive up to 6, 9, and 18 cycles of treatment with RO7283420, when treated with Q3W, Q2W, or QW dosing regimens, respectively.
Study: NCT01882335

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Peer support for exclusive breastfeeding
Description: Pregnant women were identified and randomized to peer support for exclusive breastfeeding in clusters. They were followed up for 6 months post delivery.
Study: NCT00901225

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: G-CSF plus Plerixafor
Description: On Day 5 of G-CSF mobilization,~1. if the patient's peripheral CD34+ cell count is \< 7cells/µl then 240ug/kg Plerixafor will be given in the evening prior to receiving 10µg/kg G-CSF and undergoing apheresis the next morning for up to 3 days of apheresis or until ≥ 5x10(6) cells/kg are collected.~2. if the patient's peripheral CD34+ cell count is 7 to 19 cells/ul (inclusive), apheresis will be done. If the apheresis yield is \< 1.3x10(6) CD34+ cells/kg then 240ug/kg Plerixafor will be given in the evening prior to receiving 10 µg/kg G-CSF and undergoing apheresis the next morning. If the apheresis yield is at least double that on Day 5, Plerixafor followed the next morning by G-CSF and apheresis will be repeated for up to a total of 3 days of apheresis or until 5x10(6) cells/kg are collected.
Study: NCT01074073

Intervention type: DRUG
Group type: OTHER
Intervention: Lurasidone HCl
Description: lurasidone HCl 40 mg tablets administered orally as three tablets (120 mg) once a day (QD).~Lithium 300 mg capsules administered orally as two capsules (600 mg) twice a day (BID).~On dosing days, breakfast will be served 30 minutes prior to the planned dosing time. Patients must consume the breakfast within 30 minutes or less. Dosing will take place 30 minutes after the start of breakfast.
Study: NCT03019887

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: reduction of risperidone, haloperidol, olanzapine, quetiapine, aripiprazole, paliperidone, levomepromazine, perphenazine
Study: NCT01389986

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Gum chewing
Description: Gum chewing (30 minutes in duration each time, 4 times/days at the usual time of meal, until the first flatus) in addition to conventional postoperative feeding schedule
Study: NCT01899430

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: liraglutide

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: metformin
Study: NCT01935544

Intervention type: DEVICE
Group type: OTHER
Intervention: Botulinum toxin injection
Study: NCT02171026

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dabigatran etexilate

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amiodarone

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amiodarone
Study: NCT03578107

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: improvement of quality of stroke care
Description: 1. hospital tool kits for quality improvement of reperfusion therapy ;~2. organizational stakeholder and opinion leader meetings;~3. data monitoring and feedback reports；~4. webinar for hospital teams

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: improvement of quality of stroke care
Description: 1. hospital tool kits for quality improvement of reperfusion therapy ;~2. organizational stakeholder and opinion leader meetings;~3. data monitoring and feedback reports；~4. webinar for hospital teams

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: improvement of quality of stroke care
Description: 1. hospital tool kits for quality improvement of reperfusion therapy ;~2. organizational stakeholder and opinion leader meetings;~3. data monitoring and feedback reports；~4. webinar for hospital teams
Study: NCT01025557

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dietary intervention
Description: Dietary treatments with beverages

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dietary intervention
Description: Dietary treatments with beverages

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dietary intervention
Description: Dietary treatments with beverages

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dietary intervention
Description: Dietary treatments with beverages

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dietary intervention
Description: Dietary treatments with beverages
Study: NCT03314610

Intervention type: OTHER
Intervention: Gait speed
Description: No intervention, only propose water and wait for need to void
Study: NCT03153501

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: CT-guided Abrams needle biopsy, US-guided cutting needle, medical thoracoscopy
Study: NCT02433912

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Test - Laterally positioned flap
Description: Laterally positioned flap. Systemic analgesics consisting of 750 mg of paracetamol was taken every six hours for four days. chlorhexidine gluconate (2.0%) gel applied in saturated cotton swabs twice a day for 14 days.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Control-Coronally positioned flap
Description: Coronally positioned flap. Systemic analgesics consisting of 750 mg of paracetamol was taken every six hours for four days. chlorhexidine gluconate (2.0%) gel applied in saturated cotton swabs twice a day for 14 days.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 750 mg paracetamol
Description: Systemic analgesics consisting of 750 mg of paracetamol was taken every six hours for four days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 750 mg paracetamol
Description: Systemic analgesics consisting of 750 mg of paracetamol was taken every six hours for four days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: chlorhexidine gluconate
Description: chlorhexidine gluconate (2.0%) gel applied in saturated cotton swabs twice a day for 14 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: chlorhexidine gluconate
Description: chlorhexidine gluconate (2.0%) gel applied in saturated cotton swabs twice a day for 14 days
Study: NCT02733744

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Fecal Microbiota Transplantation (FMT)
Description: FMT will be given through the ingestion of 30 capsules (15 capsules daily x 2 consecutive days)
Study: NCT00895362

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erlotinib
Description: Starting dose 100 mg by mouth 1 time every day for 28-day cycle (Pediatric starting dose 50 mg).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetuximab
Description: Loading dose of 200 mg/m\^2 (maintenance 125 mg/m\^2) by vein 1 day every week of 28-day cycle, on Days 1, 8, 15 and 22. First dose given over 2 hours and over 1 hour each subsequent time.
Study: NCT02877576

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Implantation of mixed intracerebral electrodes
Description: 5 macro electrodes with micro electrodes are implanted in internal temporal structures (amygdala, anterior and posterior hippocampus, rhinal cortex, posterior para-hippocampal gyrus).~Each electrode has 8 microcontacts, each recording the activity of 0 to 3 neurons (activity of 0 to 120 neurons/patient).

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Face detection
Description: Visualization of images of 60 unknown faces and 60 objects that are not faces (object, house, scene, animal, plant, word, letter...). Each image is showed for 500 ms and separated from following image by black screen of 1500 ms. In order to keep patient attention on image, patient will be asked to push a button at color change of fixation cross in the centre of image.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Face individualization
Description: Visualization of images of celebrities (persons known by patient), showed randomly. Each image is showed for 500 ms and separated from following image by black screen of 1500 ms. In order to keep patient attention on image, patient will be asked to push a button at color change of fixation cross in the centre of image.~Several celebrities are showed, with for each the presentation of 60 images different from that celebrity. 1 to 3 celebrities are showed (60 to 180 total images).
Study: NCT02065492

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard Chelation
Description: This will comprise of standard chelation drugs (Deferasirox or Deferoxamine or Combination of Deferoxamine and Deferiprone).The dosage and drug used will depend on ferritin levels and individual requirement, as determined by the treating hematologist and will be in accordance with the Iron chelation guidelines from Pakistan Thalassemia Society.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Standard Chelation
Description: This will comprise of standard chelation drugs (Deferasirox or Deferoxamine or Combination of Deferoxamine and Deferiprone).The dosage and drug used will depend on ferritin levels and individual requirement, as determined by the treating hematologist and will be in accordance with the Iron chelation guidelines from Pakistan Thalassemia Society.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amlodipine
Description: doses of 0.2 to 0.25 mg/kg/day PO would be given during this trial
Study: NCT02625350

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Instant noodle without soup
Description: First, fasting blood glucose was measured. Then, subjects consumed the sample (instant noodle without soup) and blood sugar level were measured at 0', 15', 30', 45', 60', 90', and 120'

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Instant noodle with soup
Description: First, fasting blood glucose was measured. Then, subjects consumed the sample (instant noodle with soup) and blood sugar level were measured at 0', 15', 30', 45', 60', 90', and 120'

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Glucose reference
Description: First, fasting blood glucose was measured. Then, subjects consumed the glucose reference and blood sugar level were measured at 0', 15', 30', 45', 60', 90', and 120'
Study: NCT04357561

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise group (Schroth best practice)
Description: Exercise program will be structured with scoliosis specific exercises (schroth best practice). Schroth best pratice is a pattern spesific scoliosis rehabilitation concept which aimes active self correction during curve pattern specific curve activities of daily life. Exercises for rotational breathing, everyday activities, spinal mobilization and corrective exercises will be specified based on the curve type and applied under the supervision of a physiotherapist.
Study: NCT03068897

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metaxalone
Description: Metaxalone 400-800mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tizanidine
Description: Tizanidine 2-4mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Baclofen
Description: Baclofen 10-20mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ibuprofen 600 mg
Description: Ibuprofen

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ibuprofen 600 mg
Description: Ibuprofen

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Ibuprofen 600 mg
Description: Ibuprofen

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ibuprofen 600 mg
Description: Ibuprofen

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Educational intervention
Description: Research personnel will provide each patient with a 15-minute educational intervention. This will be based on NIAMS's Handout on Health: Back Pain information webpage (available at http://www.niams.nih.gov/Health_Info/Back_Pain/default.asp) Research personnel will review each section of the information sheet with the patient and elicit questions.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Educational intervention
Description: Research personnel will provide each patient with a 15-minute educational intervention. This will be based on NIAMS's Handout on Health: Back Pain information webpage (available at http://www.niams.nih.gov/Health_Info/Back_Pain/default.asp) Research personnel will review each section of the information sheet with the patient and elicit questions.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Educational intervention
Description: Research personnel will provide each patient with a 15-minute educational intervention. This will be based on NIAMS's Handout on Health: Back Pain information webpage (available at http://www.niams.nih.gov/Health_Info/Back_Pain/default.asp) Research personnel will review each section of the information sheet with the patient and elicit questions.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Educational intervention
Description: Research personnel will provide each patient with a 15-minute educational intervention. This will be based on NIAMS's Handout on Health: Back Pain information webpage (available at http://www.niams.nih.gov/Health_Info/Back_Pain/default.asp) Research personnel will review each section of the information sheet with the patient and elicit questions.
Study: NCT00511758

Intervention type: PROCEDURE
Intervention: Digital Imaging
Description: Images of the cervix will be taken using different types of light and compared with the colposcopy procedure.
Study: NCT00447798

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Prevention Care Advocate
Description: Prevention Care Advocate: 8 Session intervention combining cognitive-behavioral skill building \& strengths based case management
Study: NCT04862559

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NovaCross
Description: A device that is intended to asisst interventional cardiologists during catheterization to cross and open coronary chronic total occlusions